TCIM
FLGT icon

TIAA CREF Investment Management’s Fulgent Genetics FLGT Stock Holding History

TIAA CREF Investment Management’s Portfolio FLGT Stock Details FLGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-3,605
Closed -$39K – 3146
2017
Q1 		$39K Buy
3,605
+1,690
+88% +$20K ﹤0.01% 3069
2016
Q4 		$22K Buy
+1,915
New +$18.1K ﹤0.01% 3113

Other funds holding FLGT

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
SC
Scholtz & Company Stamford, Connecticut $195M AUM 12.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
ECM
Element Capital Management New York $1.05B AUM 5.05% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TIAA CREF Investment Management's FLGT Position: Q2 2017 in Review

TIAA CREF Investment Management sold out of Fulgent Genetics (FLGT) in Q2 2017, closing a stake of 3,605 shares — an estimated $39K sold.

TIAA CREF Investment Management first reported a position in FLGT in Q4 2016 and held it in 2 quarters. The position peaked at $39K in Q1 2017. 22 funds tracked by Wall St. Rank hold FLGT as of Q2 2017.

  • TIAA CREF Investment Management reported no remaining Fulgent Genetics position as of Q2 2017 after selling out during the quarter.
  • TIAA CREF Investment Management sold 3,605 Fulgent Genetics shares in Q2 2017, an estimated $39K.
  • TIAA CREF Investment Management first reported a position in Fulgent Genetics in Q4 2016 and held it in 2 quarters.
  • TIAA CREF Investment Management's Fulgent Genetics position peaked at $39K in Q1 2017.
  • 22 funds tracked by Wall St. Rank held Fulgent Genetics as of Q2 2017.

Based on TIAA CREF Investment Management's 13F filing for Q2 2017, filed 10 Aug 2017.